EHA Guidelines for the use and reporting of patient‐reported outcomes in clinical trials of classical Philadelphia chromosome‐negative myeloproliferative neoplasms

Esther Natalie Oliva, Tatyana Ionova, Marta Sobas, Peter Loeffelhardt, Edward Laane, Sam Salek
HemaSphere · Wiley · 2026-11-17 · DOI: 10.1002/hem3.70540

Abstract

Abstract Patient‐reported outcome measures (PROMs) are increasingly used in clinical trials of classical Philadelphia chromosome‐negative myeloproliferative neoplasms (Ph‐negative MPNs; myelofibrosis [MF], polycythemia vera [PV], and essential thrombocythemia [ET]) as primary, key secondary, secondary, or exploratory endpoints. In the attached COnsensus‐based Standards for the selection of health Measurement INstruments (COSMIN) systematic review, patient‐reported outcome (PRO) assessment was planned or reported in 79 of 87 randomized controlled trials (91%), but PRO results were reported in publications for only 46 of these 79 studies (58%). The review identified 52 reports evaluating measurement properties of 12 PROMs used in classical Ph‐negative MPNs. Evidence was uneven. Myelofibrosis Symptom Assessment Form (MF‐SAF) v4.0 had the strongest measurement‐property evidence for MF symptom burden, with sufficient structural validity and internal consistency with high certainty, but inconsistent findings for reliability, construct validity, and responsiveness. Myelofibrosis Symptom Diary (MPN‐SD) had the best content‐validity evidence but limited evidence across other properties. MPN‐10/MPN‐SAF total symptom score (TSS) has substantial clinical‐trial experience and clinical familiarity, including use in pivotal development programs, although formal content‐validity evidence and some structural and construct‐validity findings remain limited or inconsistent. Generic and cancer‐specific tools, including European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire‐Core 30 (EORTC QLQ‐C30) and EuroQol 5‐Dimension instrument (EQ‐5D), remain useful for broader health‐related quality of life (HRQoL) and health‐utility questions but should not be used alone to support MPN‐specific symptom claims. These guidelines adapt established oncology PRO standards to MPN‐specific instrument, subtype, endpoint, timing, and interpretation issues. They recommend fit‐for‐purpose PROM selection, standardized self‐administration, baseline and longitudinal assessment aligned with trial objectives, prospective missing‐data mitigation, sample‐size planning for PRO endpoints, and transparent reporting in accordance with CONSORT‐PRO and related standards.

Read at publisher →

Similar articles